Search Results - "противоопухолевый препарат"

1

Academic Journal

Safety assessment and determination of a maximally tolerated dose of an RAS-GTPase inhibitor (iRAS) in the treatment of gastrointestinal tumors: preliminary results of the phase I trial ; Оценка безопасности с установлением максимально переносимой дозы ингибитора RAS-ГТФазы (Инг-Рас) для лечения опухолей желудочно-кишечного тракта: предварительные результаты исследования I фазы

Authors: Bozhenko V.K., Goncharov S.V., Kudinova E.A., Kulinich T.M., Kukoleva E.A., Filippov M.S., Bykova A.F., Knyazeva O.B., Puchkov I.A., Solodkiy V.A.

Contributors: 0

Source: Almanac of Clinical Medicine; Vol 51, No 7 (2023); 376-396 ; Альманах клинической медицины; Vol 51, No 7 (2023); 376-396 ; 2587-9294 ; 2072-0505

Subject Terms: anti-tumor agent, peritoneal carcinomatosis, Ras-GTPase inhibitor, intraperitoneal aerosol chemotherapy (PIPAC), molecular targets, clinical studies, противоопухолевый препарат, канцероматоз брюшины, ингибитор Ras-ГТФазы, внутрибрюшная аэрозольная химиотерапия (PIPAC), молекулярные мишени, клинические исследования

File Description: application/pdf

Relation: https://almclinmed.ru/jour/article/view/17182/1625; https://almclinmed.ru/jour/article/downloadSuppFile/17182/159744; https://almclinmed.ru/jour/article/downloadSuppFile/17182/159745; https://almclinmed.ru/jour/article/downloadSuppFile/17182/159746; https://almclinmed.ru/jour/article/downloadSuppFile/17182/159747; https://almclinmed.ru/jour/article/view/17182

Availability: https://almclinmed.ru/jour/article/view/17182
https://doi.org/10.18786/2072-0505-2023-51-045

View record from BASE

2

Academic Journal

Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis ; Противоопухолевый ингибитор протеинтирозинкиназ иматиниб как потенциальный корректор пневмофиброза COVID-19

Authors: Mikhaylova I.N., Treshalina N.M., Shubina I.Z., Manina I.V., Kiselevsky M.V., Lukashev A.N.

Source: Advances in Molecular Oncology; Vol 7, No 4 (2020); 20-28 ; Успехи молекулярной онкологии; Vol 7, No 4 (2020); 20-28 ; 2413-3787 ; 2313-805X

Subject Terms: antitumor drug, imatinib mesylate, tyrosine protein kinase, pneumofibrosis, COVID-19, противоопухолевый препарат, иматиниб мезилат, протеинтирозинкиназа, пневмофиброз

File Description: application/pdf

Relation: https://umo.abvpress.ru/jour/article/view/300/215; https://umo.abvpress.ru/jour/article/view/300

Availability: https://umo.abvpress.ru/jour/article/view/300
https://doi.org/10.17650/2313-805X-2020-7-4-20-28

View record from BASE

3

Academic Journal

Regorafenib: a novel drug for metastatic colorectal cancer treatment ; Регорафениб: новый препарат для лечения метастатического колоректального рака

Authors: Marina Igorevna Sekacheva, Марина Игоревна Секачева

Source: Malignant tumours; № 2 (2016); 72-80 ; Злокачественные опухоли; № 2 (2016); 72-80 ; 2587-6813 ; 2224-5057

Subject Terms: таргетная терапия, regorafenib, anticancer agent, targeted therapy, регорафениб, противоопухолевый препарат

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/236/225; http://globocan.iarc.fr/old/bar_pop.asp?selection=163643&title=Russian+Federation&sex=0&statistic=0&window=1&grid=1&color1=5&color1e=&color2=4&color2e=&orientation=1&submit =%C2%A0Execute; Wilhelm S. M., Dumas J., Adnane L., et al. Regorafenib (BAY73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–255.; Schmieder R., Hoffmann J., Becker M., et al. Regorafenib (BAY73–4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer. 2014;135:1487–1496.; Strumberg D., Scheulen M. E., Schultheis B., et al. Regorafenib (BAY73–4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722–1727).; Solimando Jr. D.A., Waddell J. A. Drug monographs: bosutinib and regorafenib. Hosp Pharm. 2013;48:190–194.; Zopf D., Heinig R., Thierauch K-H., et al. Abstract 1666: Regorafenib (BAY73–4506): preclinical pharmacology and clinical identification and quantification of its major metabolites. Cancer Res. 2010;70 (8 Supplement):1666.; Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;38:303–312.; Ricotta R., Sartore-Bianchi A., Verrioli A., Vanzulli A., Siena S. Regorafenib for metastatic colorectal cancer. Lancet. 2013;381(9877):1537.; Li J., Qin S., Xu R. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–629.; Tougeron D., Desseigne F., Etienne P. L., Dourthe L. M., Mineur L., Paule B. et al. REBECCA: a large cohort study of regorafenib (REG) in the real-life setting in patients (pts) previously treated for metastatic colorectal cancer (mCRC). Ann Oncol. 2014;25(4): iv167–209.; Van Cutsem E., Ciardiello F., Seitz J-F. et al. Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. Ann Oncol. 2015;26(4 Supplement): iv118.; https://www.malignanttumors.org/jour/article/view/236

Availability: https://www.malignanttumors.org/jour/article/view/236
https://doi.org/10.18027/2224-5057-2016-2-72-80

View record from BASE

4

Academic Journal